Terms: = Ovarian cancer AND MAML2, MAM3, 84441, ENSG00000184384, MAM-3, MLL-MAML2, Q8IZL2, KIAA1819, DKFZp686N0150, MAM2
3 results:
1. NOTCH Signaling Limits the Response of Low-Grade Serous ovarian cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract] [Full Text] [Related]
2. Integrated Genomic, Epigenomic, and Expression Analyses of ovarian cancer Cell Lines.
Papp E; Hallberg D; Konecny GE; Bruhm DC; Adleff V; Noë M; Kagiampakis I; Palsgrove D; Conklin D; Kinose Y; White JR; Press MF; Drapkin R; Easwaran H; Baylin SB; Slamon D; Velculescu VE; Scharpf RB
Cell Rep; 2018 Nov; 25(9):2617-2633. PubMed ID: 30485824
[TBL] [Abstract] [Full Text] [Related]
3. Variants in Notch signalling pathway genes, PSEN1 and maml2, predict overall survival in Chinese patients with epithelial ovarian cancer.
Xu Y; Cheng L; Dai H; Zhang R; Wang M; Shi T; Sun M; Cheng X; Wei Q
J Cell Mol Med; 2018 Oct; 22(10):4975-4984. PubMed ID: 30055028
[TBL] [Abstract] [Full Text] [Related]
